相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Real-world experience with pasireotide-LAR in resistant acromegaly: a single center 1-year observation
Maria Stelmachowska-Banas et al.
PITUITARY (2022)
Partial response to first generation SSA guides the choice and predict the outcome of second line therapy in acromegaly
Sabrina Chiloiro et al.
ENDOCRINE (2022)
Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response
Sabrina Chiloiro et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2021)
Long-term safety and efficacy of long-acting pasireotide in acromegaly
Amit Akirov et al.
ENDOCRINE (2021)
Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant
Sabrina Chiloiro et al.
ENDOCRINE (2021)
A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update
Andrea Giustina et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Pasireotide for acromegaly: long- term outcomes from an extension to the Phase III PAOLA study
Annamaria Colao et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2020)
Pituitary Tumors Centers of Excellence
Stefano Frara et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2020)
Multidisciplinary management of acromegaly: A consensus
Andrea Giustina et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2020)
How to Position Pasireotide LAR Treatment in Acromegaly
Eva C. Coopmans et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 Expression
Ammar Muhammad et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas
Gerald Raverot et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2018)
A Consensus Statement on acromegaly therapeutic outcomes
Shlomo Melmed et al.
NATURE REVIEWS ENDOCRINOLOGY (2018)
Somatotropinomas inadequately controlled with octreotide may over-respond to pasireotide: the importance of dose adjustment to achieve long-term biochemical control
Ilan Shimon et al.
HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM (2017)
In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas
Federico Gatto et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Reference Values for IGF-I Serum Concentrations: Comparison of Six Immunoassays
Philippe Chanson et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Current and Emerging Aspects of Diabetes Mellitus in Acromegaly
Stefano Frara et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2016)
Somatostatin analogs: does pharmacology impact antitumor efficacy?
Mounira Chalabi et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2014)
Pasireotide (SOM230) Demonstrates Efficacy and Safety in Patients with Acromegaly: A Randomized, Multicenter, Phase II Trial
S. Petersenn et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy
Marco Volante et al.
MODERN PATHOLOGY (2007)
分享论文
